International Clinical Trials is a company that specializes in the application of the latest scientific technologies to the pharmaceutical industry. These technologies possess great sensitivity & specificity that facilitate comparisons of drug effects on psychomotor performance & driving skills.
These unique methodologies supersede all current technologies used to evaluate the sedating properties of different drugs.
These methodologies ensure maximum commercialization of minimally sedating drugs.
There is a strong unmet medical need for medications that are safer for patients who drive cars & operate equipment.
The World Health Organization reports that road accidents claim more than 1.2 million lives each year.Road traffic injuries are the leading cause of death for the 15-29 year age group and the second most common cause of death for those aged 5-14 years.
Twenty two percent of patients on anxiolytics, antidepressants, hypnotics, antiepileptics, opiods,sedating antihistamines,hypoglycemic agents,central nervous system (CNS) stimulants,and herbals with CNS-related effects are involved in motor vehicle accidents.
Schizophrenia affects more than 21 million people worldwide and the schizophrenia market was worth $US 6.5 billion in 2014.
This illness is a chronic disabling disorder that affects around 2.4 million in the US and 3.5 million in Europe.
Thirty two percent of patients suffering from schizophrenia and schizoaffective disorders are involved in motor vehicle accidents.
Bipolar disorders affect approximately 5.7 million people in the US.
Forty to sixty eight percent of schizophrenic outpatients regularly drive automobiles.
As schizophrenic patients have double the rate of motor vehicle accidents per mile driven,our passionate mission is to find anti-psychotics that are safer for patients who drive cars.
The goal is to save lives, reduce severe trauma injuries, property damage and insurance premiums caused by serious motor vehicle accidents.
International Clinical Trials business model is based on partnerships with other pharmaceutical companies that possess minimally sedating antipsychotic compounds.
Commercial returns for low sedating antipsychotic drugs are maximised throughout their whole product life cycle by early clinical trial comparisons with heavily sedating antipsychotic compounds.
Val Schabinsky founded International Clinical Trials in 2005 and has served as director and chairman since incorporation occurred on 24 October 2011.
Previously he worked in various roles in the pharmaceutical industry at Bristol-Myers Squibb & Merck. He also pioneered the positions of medical product specialist at Janssen-Cilag & medical communications manager at Pfizer.
Prior to this, he researched the mechanism of acute tolerance to alcohol & obtained four years academic teaching experience in the Department of Pharmacology, University of Sydney.
Val holds a Bachelor of Science and a Master of Science (Pharmacology) degree from the University of Sydney.